Ostatní
Návod 
Amgen Inc.
AMGN
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
173.2B
Obrat
37B
Zisk
8B
Aktiva
90B
Dluh
55B
ROE
0%
ROA
0%
PE
24
PS
5
Cena 1R
261-346
⌀ Cena
298.68
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
29-04-2026
Poslední dividenda
13-02-2026
Profil
Amgen Inc. objevuje, vyvíjí, vyrábí a dodává humánní terapeutické prostředky po celém světě. Zaměřuje se na zánět, onkologii/hematologii, zdraví kostí, kardiovaskulární onemocnění, nefrologii a neurovědy. Mezi produkty společnosti patří Enbrel k léčbě ložiskové psoriázy, revmatoidní artritidy a psoriatické artritidy; Neulasta, která snižuje riziko infekce způsobené nízkým počtem bílých krvinek u pacientů s nádorovým onemocněním; Prolia k léčbě postmenopauzálních žen s osteoporózou; Xgeva k prevenci kostních příhod; Otezla k léčbě dospělých pacientů s ložiskovou psoriázou, psoriatickou artritidou a perorálními vředy spojenými s Behçetovou chorobou; Aranesp k léčbě nižšího než normálního počtu červených krvinek a anemických buněk Kyprolis k léčbě pacientů s recidivujícím nebo refrakterním mnohočetným myelomem; a Repatha, která snižuje riziko infarktu myokardu, cévní mozkové příhody a koronární revaskularizace. Prodává také Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor a AVSOLA. Amgen Inc. slouží poskytovatelům zdravotní péče, včetně lékařů nebo jejich klinik, dialyzačních center, nemocnic a lékáren. Své výrobky distribuuje prostřednictvím velkoobchodních distributorů léčiv a také prostřednictvím přímých distribučních kanálů. Má dohody o spolupráci se společnostmi Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; a Verastem, Inc. na vyhodnocení VS- 6766 v kombinaci s lumakrastem (Sotorasib) u pacientů s nemalobuněčným karcinomem plic, mutovaným v genu KRAS G12C. Má dohodu s Kyowa Kirin Co., Ltd. společně vyvíjet a komercializovat KHK4083, plně lidskou monoklonální protilátku anti-OX40 připravenou pro fázi 3 pro léčbu atopické dermatitidy a dalších autoimunitních onemocnění; a výzkum a vývoj spolupráce s Neumora Therapeutics, Inc. a Plexium, Inc. Amgen Inc. byla založena v roce 1980 a sídlí v Thousand Oaks, Kalifornie.
Sektor
Healthcare
Odvětví
Drug Manufacturers - General
Počet zaměstnanců
28000
Založení
1983-06-17
Podobné společnosti
$ 117.95
- $ 0.89
$ 24.16
- $ 0.28
$ 50.17
+ $ 0.51
$ 86.23
- $ 0.05
$ 209.92
- $ 0.03
$ 46.93
+ $ 0.24
$ 45.70
+ $ 0.02
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliardách (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 36.77 | 36.74 | 33.42 | 28.19 | 26.32 | 25.98 | 25.42 | 23.36 | 23.75 | 22.85 | 22.99 | 21.66 | 20.06 | 18.68 | 17.27 | 15.58 | 15.05 | |
| Cost of Revenues | 10.85 | 10.73 | 12.86 | 8.42 | 6.41 | 6.45 | 6.16 | 4.36 | 4.10 | 4.07 | 4.16 | 4.23 | 4.42 | 3.35 | 2.92 | 2.43 | 2.22 | |
| Gross Profit | 25.92 | 26.01 | 20.57 | 19.78 | 19.92 | 19.53 | 19.27 | 19.01 | 19.65 | 18.78 | 18.83 | 17.44 | 15.64 | 15.33 | 14.35 | 13.16 | 12.83 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 9.90 | 9.56 | 9.17 | 8.15 | 9.09 | 8.50 | 8.39 | 7.45 | 8.20 | 6.90 | |
| Cost of Revenues | 1.79 | 3.08 | 3.01 | 2.97 | 3.11 | 3.31 | 3.24 | 3.20 | 3.11 | 1.81 | |
| Gross Profit | 8.11 | 6.48 | 6.16 | 5.18 | 5.97 | 5.19 | 5.15 | 4.25 | 5.08 | 5.10 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 0.00 | 4.78 | 4.43 | 4.82 | 4.21 | 4.12 | 3.74 | 3.56 | 3.84 | 4.07 | 4.30 | 4.08 | 3.38 | 3.17 | 2.89 | |
| Selling General & Admin Expenses | 0.00 | 0.00 | 0.00 | 6.18 | 5.41 | 5.37 | 5.73 | 5.15 | 5.33 | 4.87 | 5.06 | 4.85 | 4.70 | 5.18 | 4.80 | 4.49 | 3.98 | |
| Depreciation & Amortization | 5.17 | 5.17 | 5.59 | 4.07 | 3.42 | 3.40 | 3.60 | 0.75 | 1.95 | 1.96 | 2.11 | 2.11 | 2.09 | 1.29 | 0.29 | 0.29 | 0.29 | |
| Total Operating Expenses | 15.63 | 15.34 | 13.31 | 11.88 | 10.35 | 10.38 | 10.13 | 9.33 | 9.38 | 8.81 | 9.04 | 8.97 | 9.45 | 9.46 | 8.77 | 8.84 | 7.29 | |
| Operating Income | 10.29 | 10.68 | 7.26 | 7.90 | 5.34 | 6.01 | 5.79 | 9.67 | 10.26 | 9.97 | 9.79 | 8.47 | 6.19 | 5.87 | 5.58 | 4.31 | 5.55 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.53 | 1.08 | ||
| Selling General & Admin Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.27 | 1.35 | ||
| Depreciation & Amortization | 1.13 | 1.31 | 1.34 | 1.39 | 1.40 | 1.40 | 1.40 | 1.40 | 1.38 | 0.90 | ||
| Total Operating Expenses | 4.16 | 3.95 | 3.51 | 4.00 | 3.66 | 3.15 | 3.24 | 3.26 | 3.81 | 3.08 | ||
| Operating Income | 3.94 | 2.53 | 2.64 | 1.18 | 2.31 | 2.05 | 1.91 | 0.99 | 1.27 | 2.02 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 0.75 | 0.67 | 0.93 | 0.63 | 0.60 | 0.47 | 0.42 | 0.49 | 0.45 | 0.38 | |
| Interest Expense | 2.77 | 2.76 | 3.16 | 2.88 | 1.41 | 1.20 | 1.26 | 1.29 | 1.39 | 1.30 | 1.26 | 1.10 | 1.07 | 1.02 | 1.05 | 0.61 | 0.60 | |
| Other Expense | -1.31 | -1.70 | -2.65 | -0.04 | 2.01 | 0.70 | 2.34 | -0.54 | -0.72 | -0.38 | -0.63 | -0.49 | -0.61 | -0.60 | -0.57 | -0.90 | -0.23 | |
| IBT | 8.98 | 8.98 | 4.61 | 7.86 | 7.35 | 6.70 | 8.13 | 9.14 | 9.55 | 9.60 | 9.16 | 7.98 | 5.59 | 5.27 | 5.01 | 4.15 | 5.32 | |
| Income Tax Expense | 1.27 | 1.27 | 0.52 | 1.14 | 0.79 | 0.81 | 0.87 | 1.30 | 1.15 | 7.62 | 1.44 | 1.04 | 0.43 | 0.18 | 0.66 | 0.47 | 0.69 | |
| Net Income | 7.71 | 7.71 | 4.09 | 6.72 | 6.55 | 5.89 | 7.26 | 7.84 | 8.39 | 1.98 | 7.72 | 6.94 | 5.16 | 5.08 | 4.35 | 3.68 | 4.63 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.82 | 0.76 | ||
| Interest Expense | 0.65 | 0.69 | 0.71 | 0.72 | 0.75 | 0.78 | 0.81 | 0.82 | 0.82 | 0.76 | ||
| Other Expense | -2.43 | 1.40 | -1.08 | 0.80 | -1.53 | 1.05 | -1.12 | -1.06 | -0.42 | -0.07 | ||
| IBT | 1.51 | 3.92 | 1.57 | 1.97 | 0.78 | 3.10 | 0.79 | -0.07 | 0.85 | 1.95 | ||
| Income Tax Expense | 0.18 | 0.71 | 0.14 | 0.24 | 0.16 | 0.27 | 0.05 | 0.05 | 0.09 | 0.22 | ||
| Net Income | 1.33 | 3.22 | 1.43 | 1.73 | 0.63 | 2.83 | 0.75 | -0.11 | 0.77 | 1.73 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $12.56 | $12.18 | $10.34 | $12.40 | $12.96 | $12.70 | $2.71 | $10.32 | $9.15 | $6.80 | $6.75 | $5.61 | $4.07 | $4.82 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $12.49 | $12.11 | $10.28 | $12.31 | $12.88 | $12.62 | $2.69 | $10.24 | $9.06 | $6.70 | $6.64 | $5.52 | $4.04 | $4.79 | |
| Shares Outstanding | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.57 | 0.59 | 0.61 | 0.66 | 0.73 | 0.75 | 0.76 | 0.76 | 0.75 | 0.78 | 0.91 | 0.96 | |
| Diluted Shares Outstanding | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.57 | 0.59 | 0.61 | 0.67 | 0.74 | 0.75 | 0.77 | 0.77 | 0.77 | 0.79 | 0.91 | 0.97 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.43 | $3.23 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.42 | $3.22 | ||
| Shares Outstanding | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | ||
| Diluted Shares Outstanding | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 9.30 | 11.97 | 10.94 | 7.63 | 7.99 | 6.27 | 6.04 | 6.95 | 3.80 | 3.24 | 4.14 | 3.73 | 3.81 | 3.26 | 6.95 | 3.29 | |
| Short Term Investments | 0.00 | 0.00 | 10.94 | 1.68 | 0.05 | 4.38 | 2.87 | 22.36 | 37.88 | 34.84 | 27.24 | 23.30 | 15.60 | 20.80 | 13.70 | 14.14 | |
| Total Cash & ST Investments | 9.30 | 11.97 | 10.94 | 9.31 | 8.04 | 10.65 | 8.91 | 29.30 | 41.68 | 38.09 | 31.38 | 27.03 | 19.40 | 24.06 | 20.64 | 17.42 | |
| Accounts Receivable | 6.93 | 7.50 | 7.94 | 5.56 | 4.90 | 4.53 | 4.06 | 3.58 | 3.24 | 3.17 | 3.00 | 2.55 | 2.70 | 2.52 | 2.90 | 2.34 | |
| Inventory | 8.00 | 7.00 | 9.52 | 4.93 | 4.09 | 3.89 | 3.58 | 2.94 | 2.83 | 2.75 | 2.44 | 2.65 | 3.02 | 2.74 | 2.48 | 2.02 | |
| Other Current Assets | 2.98 | 2.56 | 1.93 | 2.39 | 2.37 | 2.08 | 1.89 | 1.79 | 1.73 | 2.02 | 1.71 | 2.49 | 2.25 | 1.89 | 22.21 | 18.77 | |
| Total Current Assets | 27.21 | 29.03 | 30.33 | 22.19 | 19.39 | 21.14 | 18.44 | 37.62 | 49.48 | 46.01 | 38.52 | 34.71 | 27.37 | 31.21 | 27.59 | 23.13 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 9.45 | 8.03 | 8.81 | 11.97 | 9.01 | 9.30 | 9.71 | 10.94 | 34.74 | 34.25 | |
| Short Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.94 | 0.00 | 0.00 | |
| Total Cash & ST Investments | 9.45 | 8.03 | 8.81 | 11.97 | 9.01 | 9.30 | 9.71 | 10.94 | 34.74 | 34.25 | |
| Accounts Receivable | 8.49 | 8.70 | 8.13 | 7.50 | 7.32 | 6.93 | 6.78 | 7.94 | 6.15 | 5.83 | |
| Inventory | 6.35 | 6.58 | 6.73 | 7.00 | 7.36 | 8.00 | 8.72 | 9.52 | 5.03 | 4.98 | |
| Other Current Assets | 3.60 | 3.42 | 3.26 | 2.56 | 3.08 | 2.98 | 2.82 | 1.93 | 2.57 | 2.32 | |
| Total Current Assets | 27.89 | 26.73 | 26.93 | 29.03 | 26.77 | 27.21 | 28.03 | 30.33 | 48.48 | 47.38 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 6.10 | 6.54 | 6.59 | 5.43 | 5.18 | 4.89 | 4.93 | 4.96 | 4.99 | 4.96 | 4.91 | 5.22 | 5.35 | 5.33 | 5.42 | 5.52 | |
| Goodwill | 18.62 | 18.64 | 18.63 | 15.53 | 14.89 | 14.69 | 14.70 | 14.70 | 14.76 | 14.75 | 14.79 | 14.79 | 14.97 | 12.66 | 11.75 | 11.33 | |
| Intangible Assets | 30.17 | 27.70 | 32.64 | 16.08 | 15.18 | 16.59 | 19.41 | 7.44 | 8.61 | 10.28 | 11.64 | 12.69 | 13.26 | 3.97 | 2.58 | 2.23 | |
| Long-Term Investments | 1.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.41 | 0.00 | 0.00 | 0.00 | |
| Other Long-Term Assets | 7.65 | 9.93 | 8.96 | 5.90 | 6.52 | 5.64 | 2.22 | 1.70 | 2.12 | 1.63 | 1.72 | 1.59 | 1.77 | 1.13 | 1.52 | 1.27 | |
| Total Long-Term Assets | 63.70 | 62.81 | 66.82 | 42.94 | 41.78 | 41.80 | 41.27 | 28.80 | 30.48 | 31.62 | 33.06 | 34.30 | 38.76 | 23.09 | 21.28 | 20.36 | |
| Total Assets | 90.91 | 91.84 | 97.15 | 65.12 | 61.17 | 62.95 | 59.71 | 66.42 | 79.95 | 77.63 | 71.58 | 69.01 | 66.13 | 54.30 | 48.87 | 43.49 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 7.22 | 6.86 | 6.68 | 6.54 | 6.16 | 6.10 | 6.00 | 5.94 | 5.56 | 5.53 | |
| Goodwill | 18.68 | 18.67 | 18.65 | 18.64 | 18.66 | 18.62 | 18.57 | 18.63 | 15.51 | 15.53 | |
| Intangible Assets | 23.14 | 24.61 | 25.72 | 27.70 | 28.92 | 30.17 | 31.37 | 32.64 | 13.15 | 14.63 | |
| Long-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.71 | 1.22 | 4.86 | |
| Other Long-Term Assets | 13.22 | 11.02 | 11.39 | 9.93 | 10.38 | 8.82 | 9.01 | 9.61 | 7.84 | 7.19 | |
| Total Long-Term Assets | 62.26 | 61.16 | 62.44 | 62.81 | 64.12 | 63.70 | 64.95 | 66.82 | 42.06 | 42.89 | |
| Total Assets | 90.14 | 87.90 | 89.37 | 91.84 | 90.88 | 90.91 | 92.98 | 97.15 | 90.53 | 90.27 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 2.27 | 1.91 | 1.59 | 1.57 | 1.37 | 1.42 | 1.37 | 1.21 | 1.35 | 0.92 | 0.97 | 1.21 | 0.79 | 0.91 | 0.64 | 0.72 | |
| Short-Term Debt | 5.53 | 3.55 | 1.44 | 1.59 | 0.09 | 0.09 | 2.95 | 4.42 | 1.15 | 4.40 | 2.25 | 0.50 | 2.51 | 2.50 | 0.08 | 2.49 | |
| Other Current Liabilities | 15.99 | 17.64 | 13.70 | 12.52 | 10.73 | 10.14 | 8.51 | 7.86 | 6.52 | 5.88 | 5.45 | 5.30 | 4.66 | 4.79 | 5.03 | 3.37 | |
| Current Liabilities | 21.52 | 23.10 | 18.39 | 15.69 | 12.18 | 11.65 | 12.84 | 13.49 | 9.02 | 11.20 | 8.67 | 7.01 | 7.95 | 8.10 | 5.75 | 6.57 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 2.84 | 3.01 | 2.41 | 1.91 | 2.15 | 2.27 | 1.63 | 1.59 | 1.36 | 1.21 | |
| Short-Term Debt | 2.15 | 2.44 | 3.37 | 3.55 | 3.54 | 5.53 | 3.96 | 1.56 | 1.43 | 2.17 | |
| Other Current Liabilities | 16.80 | 15.02 | 17.23 | 17.64 | 14.62 | 13.72 | 14.13 | 13.58 | 14.17 | 13.72 | |
| Current Liabilities | 21.79 | 20.48 | 23.01 | 23.10 | 20.31 | 21.52 | 19.71 | 18.39 | 16.95 | 17.10 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 57.12 | 56.55 | 63.86 | 37.35 | 33.22 | 32.90 | 26.95 | 29.51 | 34.19 | 30.19 | 29.31 | 30.22 | 29.62 | 24.03 | 21.34 | 10.87 | |
| Capital Leases | 0.00 | 0.78 | 0.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Def. Tax Liability | 1.78 | 1.62 | 2.35 | 0.00 | 0.00 | 0.00 | 0.61 | 0.86 | 1.17 | 2.44 | 2.24 | 3.46 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Liabilities | 84.98 | 85.96 | 90.92 | 61.46 | 54.47 | 53.54 | 50.03 | 53.92 | 54.71 | 47.75 | 43.49 | 43.23 | 44.03 | 35.24 | 29.84 | 19.54 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 52.43 | 53.76 | 54.01 | 56.55 | 56.85 | 57.12 | 60.06 | 63.86 | 59.04 | 59.38 | |
| Capital Leases | 0.00 | 0.00 | 0.00 | 0.78 | 0.00 | 0.00 | 0.00 | 0.69 | 0.00 | 0.00 | |
| Def. Tax Liability | 1.46 | 1.39 | 1.51 | 1.62 | 1.71 | 1.78 | 1.86 | 2.35 | 0.00 | 0.00 | |
| Total Liabilities | 80.52 | 80.47 | 83.16 | 85.96 | 83.36 | 84.98 | 87.96 | 90.92 | 82.88 | 83.49 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 33.20 | 33.53 | 33.07 | 32.51 | 32.10 | 31.80 | 31.53 | 31.25 | 30.99 | 30.78 | 30.65 | 30.41 | 29.89 | 29.34 | 27.78 | 27.30 | |
| Retained Earnings | -27.12 | -27.59 | -26.55 | -28.62 | -24.60 | -21.41 | -21.33 | -17.98 | -5.07 | -0.44 | -2.09 | -4.62 | -7.63 | -10.42 | -8.92 | -3.51 | |
| Comprehensive Income | -0.16 | -0.07 | -0.29 | -0.23 | -0.80 | -0.99 | -0.53 | -0.77 | -0.68 | -0.47 | -0.48 | -0.01 | -0.16 | 0.15 | 0.17 | 0.15 | |
| Total Common Equity | 5.93 | 5.88 | 6.23 | 3.66 | 6.70 | 9.41 | 9.67 | 12.50 | 25.24 | 29.88 | 28.08 | 25.78 | 22.10 | 19.06 | 19.03 | 23.94 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 33.84 | 33.68 | 33.58 | 33.53 | 33.39 | 33.20 | 33.08 | 33.07 | 32.75 | 32.60 | |
| Retained Earnings | -23.80 | -25.71 | -27.14 | -27.59 | -25.53 | -27.12 | -27.87 | -26.55 | -24.97 | -25.54 | |
| Comprehensive Income | -0.42 | -0.54 | -0.23 | -0.07 | -0.34 | -0.16 | -0.19 | -0.29 | -0.13 | -0.28 | |
| Total Common Equity | 9.62 | 7.43 | 6.21 | 5.88 | 7.53 | 5.93 | 5.02 | 6.23 | 7.66 | 6.78 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 62.65 | 60.10 | 64.61 | 38.95 | 33.31 | 32.99 | 29.90 | 33.93 | 35.34 | 34.60 | 31.56 | 30.72 | 32.13 | 26.53 | 21.43 | 13.36 | |
| Book Value | 5.93 | 5.88 | 6.23 | 3.66 | 6.70 | 9.41 | 9.67 | 12.50 | 25.24 | 29.88 | 28.08 | 25.78 | 22.10 | 19.06 | 19.03 | 23.94 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book Value | 9.62 | 7.43 | 6.21 | 5.88 | 7.53 | 5.93 | 5.02 | 6.23 | 7.66 | 6.78 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 3.13 | 7.71 | 4.09 | 6.72 | 6.55 | 5.89 | 7.26 | 7.84 | 8.39 | 1.98 | 7.72 | 6.94 | 5.16 | 5.08 | 4.35 | 3.68 | 4.63 | |
| Depreciation & Amortization | 5.07 | 5.17 | 5.59 | 4.07 | 3.42 | 3.40 | 3.60 | 2.21 | 1.95 | 1.96 | 2.11 | 2.11 | 2.09 | 1.29 | 1.09 | 1.06 | 1.02 | |
| Stock-Based Compensation | 0.73 | 0.00 | 0.53 | 0.43 | 0.40 | 0.34 | 0.33 | 0.31 | 0.31 | 0.33 | 0.31 | 0.32 | 0.41 | 0.40 | 0.36 | 0.34 | 0.35 | |
| Change Working Capital | -1.42 | -1.98 | 2.37 | -0.48 | -0.73 | -1.19 | -0.22 | -0.73 | 0.62 | 7.91 | 0.00 | 0.71 | 1.12 | -0.39 | -0.05 | 0.37 | -0.30 | |
| Change In Accounts Receivable | -0.47 | -2.68 | 0.44 | 0.00 | -0.75 | -0.43 | -0.43 | -0.50 | -0.38 | -0.06 | -0.21 | -0.42 | 0.14 | -0.04 | 0.35 | -0.56 | -0.21 | |
| Change In Accounts Payable | 0.64 | 0.43 | 0.31 | -0.40 | 0.15 | -0.07 | 0.05 | 0.16 | -0.14 | 0.42 | -0.04 | -0.01 | 0.41 | -0.18 | 0.16 | -0.10 | 0.14 | |
| Change In Inventories | 2.05 | 0.89 | 2.53 | 0.49 | -0.74 | -0.17 | -0.22 | -0.07 | 0.00 | 0.13 | -0.08 | 0.48 | 0.33 | -0.01 | -0.15 | -0.38 | 0.15 | |
| Other Non-cash Items | 4.28 | -0.22 | 0.14 | -0.99 | 1.28 | 1.28 | -0.20 | -0.19 | 0.39 | 0.33 | 0.03 | -0.40 | -0.12 | 0.10 | 0.10 | 0.07 | 0.26 | |
| Cash from Operations | 6.45 | 0.00 | 0.00 | 8.47 | 9.72 | 9.26 | 10.50 | 9.15 | 11.30 | 11.18 | 10.35 | 9.08 | 8.56 | 6.29 | 5.88 | 5.12 | 5.79 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.33 | 3.22 | 1.43 | 1.73 | 0.63 | 2.83 | 0.75 | -0.11 | 0.77 | 1.73 | |
| Depreciation & Amortization | 1.13 | 1.31 | 1.34 | 1.39 | 1.40 | 1.40 | 1.40 | 1.40 | 1.38 | 0.90 | |
| Stock-Based Compensation | 0.00 | 0.13 | 0.16 | 0.09 | 0.13 | 0.14 | 0.16 | 0.10 | 0.47 | 0.00 | |
| Change Working Capital | -1.87 | 1.66 | -0.76 | -1.02 | 2.08 | 0.86 | 0.12 | -0.69 | -0.90 | 0.05 | |
| Change In Accounts Receivable | -1.08 | 0.22 | -0.52 | -1.31 | 0.47 | -0.34 | -0.18 | 0.49 | -0.43 | -0.34 | |
| Change In Accounts Payable | -0.48 | -0.17 | 0.59 | 0.50 | -0.23 | -0.12 | 0.64 | 0.02 | -0.19 | 0.16 | |
| Change In Inventories | 0.12 | 0.24 | 0.24 | 0.29 | 0.32 | 0.68 | 0.72 | 0.81 | 0.57 | -0.05 | |
| Other Non-cash Items | 1.02 | -1.60 | 0.53 | -0.55 | 0.87 | -1.54 | 0.42 | 0.39 | -0.56 | 0.68 | |
| Cash from Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.54 | 2.76 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.97 | -1.86 | -1.10 | -1.11 | -0.94 | -0.88 | -0.61 | -0.62 | -0.74 | -0.66 | -0.84 | -0.65 | -1.00 | -0.69 | -0.69 | -0.57 | -0.58 | |
| Acquisitions | -26.99 | -0.05 | 0.00 | -26.99 | -3.73 | -2.69 | -3.22 | -13.62 | 0.20 | -0.02 | -0.02 | -0.36 | -0.17 | -9.43 | -2.39 | -0.70 | 0.00 | |
| Investments | 26.99 | 0.00 | 0.00 | 0.00 | -2.59 | -8.90 | -8.48 | -9.39 | -18.74 | -33.61 | -28.09 | -25.98 | -25.88 | -21.97 | -26.24 | -21.18 | -14.60 | |
| Sales of Investment | 0.00 | 0.00 | 0.00 | 1.67 | 1.22 | 13.23 | 6.98 | 29.39 | 33.77 | 30.41 | 20.42 | 21.56 | 20.90 | 24.21 | 19.37 | 21.62 | 11.13 | |
| Other Investing Activities | -26.82 | 0.00 | 0.00 | 0.23 | -0.01 | -0.04 | -0.08 | -0.05 | -0.15 | -0.15 | -0.12 | -0.12 | 0.40 | -0.59 | -0.04 | 0.05 | -0.10 | |
| Cash from Investing | -27.79 | 0.00 | 0.00 | -26.20 | -6.04 | 0.73 | -5.40 | 5.71 | 14.34 | -4.02 | -8.66 | -5.55 | -5.75 | -8.47 | -9.99 | -0.79 | -4.15 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.64 | -0.44 | -0.37 | -0.41 | -0.37 | -0.26 | -0.24 | -0.23 | -0.25 | -0.25 | |
| Acquisitions | -0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -26.99 | 0.00 | |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.99 | 0.00 | |
| Sales of Investment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -26.84 | -0.01 | |
| Cash from Investing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -27.09 | -0.26 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -6.46 | 0.00 | 0.00 | 25.68 | 0.00 | -4.15 | -6.45 | -4.51 | -1.12 | -4.41 | -3.73 | -2.40 | -5.61 | -3.37 | -0.12 | -3.26 | 0.00 | |
| Debt Issued | 7.56 | 60.10 | -4.51 | 51.34 | 5.64 | 4.47 | 9.53 | 0.49 | -0.29 | 5.15 | 6.77 | 3.24 | 4.19 | 8.97 | 5.22 | 11.33 | 13.36 | |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.95 | 8.91 | 0.00 | 0.00 | 4.48 | 0.06 | 0.08 | 0.19 | 0.30 | 1.29 | 11.15 | 0.08 | |
| Repurchase of Common Stock | 0.00 | 0.00 | -0.20 | 0.00 | -6.36 | -4.98 | -3.49 | -7.70 | -17.79 | -3.16 | -2.97 | -1.87 | -0.14 | -0.83 | -4.61 | -8.32 | -3.79 | |
| Dividends Paid | -4.70 | 0.00 | 0.00 | -4.56 | -4.20 | -4.01 | -3.76 | -3.51 | -3.51 | -3.37 | -3.00 | -2.40 | -1.85 | -1.42 | -1.12 | -0.50 | 0.00 | |
| Other Financing Activities | 7.55 | 0.00 | 0.00 | -0.07 | 6.52 | -0.08 | -0.09 | -0.04 | -0.07 | -0.14 | 7.03 | 3.46 | 4.53 | 8.05 | 4.98 | 0.25 | 2.47 | |
| Cash from Financing | -3.61 | 0.00 | 0.00 | 21.05 | -4.04 | -8.27 | -4.87 | -15.77 | -22.49 | -6.59 | -2.60 | -3.12 | -2.88 | 2.73 | 0.42 | -0.67 | -1.23 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.75 | |
| Debt Issued | 54.59 | -1.62 | -1.18 | -2.72 | -0.30 | -2.25 | -1.38 | -0.59 | 4.15 | -0.33 | |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.14 | -1.14 | |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.89 | -0.12 | |
| Cash from Financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.75 | -2.01 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -24.95 | -2.84 | 1.03 | 3.32 | -0.36 | 1.72 | 0.23 | -0.91 | 3.15 | 0.56 | -0.90 | 0.41 | -0.07 | 0.55 | -3.69 | 3.66 | 0.40 | |
| Closing Cash Balance | 9.30 | 9.13 | 11.97 | 10.94 | 7.63 | 7.99 | 6.27 | 6.04 | 6.95 | 3.80 | 3.24 | 4.14 | 3.73 | 3.81 | 3.26 | 6.95 | 3.29 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -0.32 | 1.42 | -0.78 | -3.16 | 2.96 | -0.29 | -0.41 | -1.24 | -23.80 | 0.49 | |
| Closing Cash Balance | 9.13 | 9.45 | 8.03 | 8.81 | 11.97 | 9.01 | 9.30 | 9.71 | 10.94 | 34.74 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 5.48 | 8.10 | 10.39 | 7.36 | 8.79 | 8.38 | 9.89 | 8.53 | 10.56 | 10.51 | 9.52 | 8.43 | 7.55 | 5.60 | 5.19 | 4.55 | 5.21 | |
| Real Free Cash Flow | 4.75 | 8.10 | 9.86 | 6.93 | 8.38 | 8.04 | 9.56 | 8.22 | 10.25 | 10.18 | 9.21 | 8.11 | 7.14 | 5.20 | 4.83 | 4.21 | 4.85 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.96 | 4.25 | 1.91 | 0.98 | 4.40 | 3.31 | 2.22 | 0.46 | 0.29 | 2.51 | |
| Real Free Cash Flow | 0.96 | 4.12 | 1.75 | 0.90 | 4.27 | 3.18 | 2.06 | 0.36 | -0.18 | 2.51 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 24.5 | 23.1 | 86.1 |
| P/S | 5.1 | 5.2 | 578 |
| P/B | 19.6 | 13.3 | 582.9 |
| P/FCF | 24.4 | 16.9 | 10581.1 |
| Market cap | $173.2 | $145.3 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 49.2 % | 0 % |
| Debt to Income | 707.9 % | 674.5 % | 0 % |
| Debt to Free cash flow | 706.1 % | 22.6 % | 0 % |
| Interest expense percentage | 26.9 % | 18.7 % | 7 % |
| Current ratio | 1.3 | 3.3 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 80.2 % | 61.1 % | 0 % |
| ROA | 8.6 % | 8.4 % | 0 % |
| CapEx to Revenue | 5.1 % | 3.5 % | 10.5 % |
| RaD to Revenue | 0 % | 17.7 % | 0 % |
| ROEM | 1,313,178.6 | 17203.1 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 70.5 % | 78.4 % | 77.7 % |
| Operating margin | 28 % | 33.7 % | 29.4 % |
| Net margin | 21 % | 25.9 % | 22.3 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 2.1 % | 0 % |
| Dividend payout percentage | 0 % | 50.5 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 543.0 mil | 689.7 mil |
| Employee count | 28.0 tis | 15.2 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
